Login / Signup

DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk.

Daniela Justa-SchuchMaria Silva-GarciaEsther PillaMichael EngelkeMarkus KilischChristof LenzUlrike MöllerFumihiko NakamuraHenning UrlaubRuth Geiss-Friedlander
Published in: eLife (2016)
The aminopeptidase DPP9 removes dipeptides from N-termini of substrates having a proline or alanine in second position. Although linked to several pathways including cell survival and metabolism, the molecular mechanisms underlying these outcomes are poorly understood. We identified a novel interaction of DPP9 with Filamin A, which recruits DPP9 to Syk, a central kinase in B-cell signalling. Syk signalling can be terminated by degradation, requiring the ubiquitin E3 ligase Cbl. We show that DPP9 cleaves Syk to produce a neo N-terminus with serine in position 1. Pulse-chases combined with mutagenesis studies reveal that Ser1 strongly influences Syk stability. Furthermore, DPP9 silencing reduces Cbl interaction with Syk, suggesting that DPP9 processing is a prerequisite for Syk ubiquitination. Consistently, DPP9 inhibition stabilizes Syk, thereby modulating Syk signalling. Taken together, we demonstrate DPP9 as a negative regulator of Syk and conclude that DPP9 is a novel integral aminopeptidase of the N-end rule pathway.
Keyphrases
  • tyrosine kinase
  • epidermal growth factor receptor
  • signaling pathway
  • crispr cas
  • gene expression
  • drug delivery
  • transcription factor
  • insulin resistance
  • small molecule
  • cancer therapy